Company intelligence / Profile preview

TRB Pharma

Ownership: Private
Development stage: Commercial

Overview

The company has established products in the market, particularly OSTENIL® which has been used for over 20 years for osteoarthritis treatment with proven efficacy and safety[5]

Therapeutic areas: Metabolic DisordersRheumatologyOphthalmologyNeurologyInfectious Diseases
Modalities: Hyaluronic acid formulationssmall molecules
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

diacerein

Commercial

Indications: Osteoarthritis, COVID-19

Beyond the preview

Go deeper on TRB Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRB Pharma.

Explore the full profile